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Abstract
Behçet’s disease is a complex vasculitis of unknown etiology.
Abundant neutrophils suggest the involvement of innate immunity.
Cytokines are skewed to the T-helper-1 pattern. Few sterile organs
are easily accessible for analysis in Behçet’s disease. Cañete and
coworkers identify inflamed joints as a feasible model and suggest
the involvement of innate immunity in Behçet’s disease.
In a recent issue of Arthritis Research and Therapy, Cañete
and coworkers [1] describe a model for studying the immuno-
pathology of Behçet’s disease (BD) by analyzing inflammatory
cells, tissue, and cytokines in inflamed joints from BD
patients. The etiology of BD is obscure but it is considered to
be a complex systemic vasculitis, caused by T-helper-1 (Th1)
cytokine skewed neutrophilic and lymphohistiocytic inflam-
mation. Hence, an understanding of how cells and cytokines
function in inflamed tissues is important in terms of develop-
ing therapeutic interventions [2]. A good example of how
mechanistic insight can lead to effective treatment is that BD
disease symptoms can be effectively and rapidly reduced by
blocking tumor necrosis factor (TNF)-α, a key cytokine in BD
[3]. Activation of BD can be triggered by exogenous factors
such as skin damage, introduction of bacterial components,
viruses and stress subsequently leading to inflammation [4].
A normal inflammatory response is rapid, non-specific, and
self-limiting. It involves a carefully balanced reaction between
activated inflammatory cells and an exogenous trigger. In
inflammatory disorders such as BD, this response is
unbalanced and causes excessive damage to the host. The
association of human leukocyte antigen (HLA)-B51 with BD
and hyperactive neutrophils stresses the importance of innate
immunity in the pathogenesis of the disease [5]. Other factors
supporting participation of the innate immune system in BD
include the following: prevalence of symptoms in body sites
in close contact with the outside environment (skin and
mucosa); the presence of hypersensitive T cells; Toll-like
receptor expression in affected cells; and hyperactive
neutrophilic and CD8+ T-cell responses to heat shock
proteins or bacterial cell wall fragments [2,4]. Cytokines that
are involved in BD are largely pro-inflammatory (IL-1β, IL-8, IL-
10, TNF-α, and IFN-γ). Peripheral T cells in BD patients
predominantly exhibit a Th1-type pattern of cytokine
expression [6].
How does the study of Cañete and coworkers [1] add to the
biomechanistic studies that have already been conducted in
BD? First, in contrast to most of those studies, the analyses
by Cañete and coworkers were conducted in untreated
patients. In an uncommon disease such as BD, few studies in
naïve patients are reported. In rheumatoid arthritis (RA), for
example, early and aggressive treatment is considered
mandatory if an optimal therapeutic outcome is to be
achieved. It will therefore be of great therapeutic importance
to identify possible initiating factors in BD also by testing
therapy-naïve patients. This is especially important for the
irreversible ophthalmic manifestations of the disease.
Second, it is important that representative tissue is studied. In
BD most mechanistic studies are conducted in blood
samples; predominantly, testing of circulating cytokines or in
vitro peripheral blood mononuclear cells is done. Th1
cytokines are involved, and hyperactive neutrophils and
hyper-reactive T cells are held responsible for the symptoms
observed [7]. However, BD is an inflammatory disorder
involving tissues such as skin, joint, eye, gut, brain, and oral
and genital mucosa [2,4]. It is therefore mandatory to be sure
that observations in blood are representative of bio-
mechanisms at the tissue level.
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Mucosal tissue is predominantly involved in BD, and micro-
organisms from the external environment can readily influence
observations in inflammatory cells. On the other hand, those
micro-organisms are also capable of stimulating an immune
response in BD. Most tissue studies of the pathophysiology
of BD are conducted in skin. One of the unique and disease-
specific features of BD is the occurrence of a positive skin
pathergy reaction (SPR), which is observed in 30% to 75%
of all BD patients [2,4]. Neutrophils and subsequently
lymphohistiocytic cells may be observed in sterile lesions
following a sterile needle prick [8]. Representing endothelial
injury and functioning as leukocyte trafficking factors, cell
adhesion molecules (intercellular adhesion molecule-1 and
vascular cell adhesion molecule-1) and endothelial growth
factor markers such as E-selectin, P-selectin, and endoglin
are linked to SPR [9]. Infiltrating cells are mainly of the
HLA-DR+/CD3+/CD4+/CD45RO+ type [10]. Other observa-
tions include mature dendritic cells; monocytes; (regulatory)
T cells; elevated levels of IFN-γ, IL-12-p40 and IL-15; MIP3-α
(macrophage inflammatory protein-3α); IP-10 (IFN-inducible
protein-10); Mig (monokine induced by IFN-γ); iTac
(interferon-inducible T cell chemo-attractant); and adhesion
molecules [11].
Studies of ocular BD show elevated Vγ9Vδ2 (CD4-/CD8-)
and CD8brightCD56+ T cells, which are probably different
from those found infiltrating the SPR [12]. Cytokines found to
be elevated in ocular fluid from BD patients with active uveitis
include IFN-γ, TNF-α, and IL-15 [13]. It must be stressed,
however, that aqueous humor is seldom studied because it is
difficult to obtain samples; it is only evaluated in intensively
and chronically treated BD patients.
In contrast to most of the inflamed organs in BD, the joint is
sterile and frequently involved in BD. Cañete and coworkers
exploit this readily accessible model, which has not often
been studied in BD. Studies of BD arthropathy dating back
more than 30 years predominantly revealed neutrophillic infil-
tration, depending on the stage and treatment of the disease.
A more recent study of synovial fluid (SF) from BD patients
identified increased levels of chemokines (C-X-C chemokine
ligand-9 and -10) related to Th1-directed inflammation [14].
Cañete’s group has studied SF extensively in various other
arthropathies, such as spondyloarthropathy (SpA) and RA,
and comparisons may be made with historical data.
Comparing SF samples between SpA and other rheumatic
diseases (RA, juvenile SpA, juvenile polyarthritis, and juvenile
oligoarthritis) revealed similarities only in terms of the
presence of CD3+, CD4+, and CD8+ cells [15].
In the study presented Cañete and coworkers [1] conclude
that psoriatic arthritis (PsA) resembles BD clinically; a further
similarity is the presence of neutrophils in SF from PsA
patients. Increased levels of intra-articular CD15+ neutrophils,
CD3+ T cells, and perforin were identified in SF from active
BD patients relative to SF from patients with PsA. This
emphasizes that innate immunity is also involved in early BD
and interacts with adaptive immunity, as reflected by the
presence of perforin, presumably secreted by CD3+ T cells. It
might therefore be of interest to conduct further studies of
these naïve T cells and cytokines in sterile SF in order to
relate these observations to immunological patterns that have
already been described in tissues that are exposed to
exogenous factors, or more intensively treated BD patients.
These results can then be compared with various other
inflammatory diseases in order to obtain greater insight into
the immune-related etiology of BD and to develop more
specific, molecular based immunotherapies. Examples may
include targeting cytokines (IL-1, IL-10, or IL-6) and use of
agents that interfere with lymphocyte action.
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